GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Everest Medicines Ltd (HKSE:01952) » Definitions » Tax Expense

Everest Medicines (HKSE:01952) Tax Expense : HK$0.0 Mil (TTM As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Everest Medicines Tax Expense?

Everest Medicines's tax expense for the months ended in Dec. 2024 was HK$0.0 Mil. Its tax expense for the trailing twelve months (TTM) ended in Dec. 2024 was HK$0.0 Mil.


Everest Medicines Tax Expense Historical Data

The historical data trend for Everest Medicines's Tax Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Everest Medicines Tax Expense Chart

Everest Medicines Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Tax Expense
Get a 7-Day Free Trial - - 0.01 - -

Everest Medicines Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Tax Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 - - - -

Everest Medicines Tax Expense Calculation

Tax paid by the company. It is computed in by multiplying the income before tax number, as reported to shareholders, by the appropriate tax rate. In reality, the computation is typically considerably more complex due to things such as expenses considered not deductible by taxing authorities ("add backs"), the range of tax rates applicable to various levels of income, different tax rates in different jurisdictions, multiple layers of tax on income, and other issues.

Tax Expense for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Everest Medicines  (HKSE:01952) Tax Expense Explanation

In the long run, income before tax and taxable income will likely be more similar than they are in any given period. If the one is less in earlier years, then it will be greater in later years. Deferred taxes will reverse themselves in the long run and in total will zero out, unless there is something like a change in tax rates in the intervening period. A deferred tax payable results from a tax break in the early years and will reverse itself in later years; a deferred tax receivable results from more taxes being paid in early years than the tax expense reported to shareholders and will again reverse itself in later years. The deferred tax amount is computed by estimating the amount and the timing of the reversal and multiplying that by the appropriate tax rates.


Everest Medicines Tax Expense Related Terms

Thank you for viewing the detailed overview of Everest Medicines's Tax Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Everest Medicines Business Description

Traded in Other Exchanges
Address
1168 West Nanjing Road, 16th Floor, CITIC Pacific Plaza, Jing’an District, Shanghai, CHN, 200041
Everest Medicines Ltd is a biopharmaceutical company that integrates discovery, licensing, clinical development, commercialization, and manufacturing of potentially novel or differentiated therapies and vaccines to address critical unmet medical needs initially in the Asia Pacific markets and eventually around the world. Its product pipeline includes; Nefecon (TarpeyoTM), EVER001 (previously known as XNW1011), PTX-COVID19-B, Eravacycline (Xerava), EVER206 (also known as SPR206), and others.
Executives
Fu Wei 2307 Founder of a discretionary trust who can infl
Nova Aqua Limited 2201 Interest of corporation controlled by you
C-bridge Capital Gp Iv, Ltd. 2201 Interest of corporation controlled by you
C-bridge Healthcare Fund Gp Iv, L.p. 2201 Interest of corporation controlled by you
C-bridge Healthcare Fund Iv, L.p. 2201 Interest of corporation controlled by you
Tf Capital Iv Ltd. 2201 Interest of corporation controlled by you
C-bridge Capital Gp, Ltd. 2501 Other
C-bridge Healthcare Fund Gp Ii, L.p. 2501 Other
C-bridge Healthcare Fund Ii, L.p. 2501 Other
C-bridge Investment Everest Limited 2501 Other
Tf Capital Ii Ltd. 2501 Other
Everest Management Holding Co., Ltd. 2101 Beneficial owner
Fu Wei 2307 Founder of a discretionary trust who can infl
C-bridge Joint Value Creation Limited 2201 Interest of corporation controlled by you
Kolchinsky Anna Inge Leonore Haas 2202 Interest of your spouse

Everest Medicines Headlines

No Headlines